Skip to main content
The New England Journal of Medicine homepage

SARS-CoV-2 Infection in Children

Published March 18, 2020
N Engl J Med 2020;382:1663-1665
DOI: 10.1056/NEJMc2005073

To the Editor:

As of March 10, 2020, the 2019 novel coronavirus (SARS-CoV-2) has been responsible for more than 110,000 infections and 4000 deaths worldwide, but data regarding the epidemiologic characteristics and clinical features of infected children are limited.1-3 A recent review of 72,314 cases by the Chinese Center for Disease Control and Prevention showed that less than 1% of the cases were in children younger than 10 years of age.2 In order to determine the spectrum of disease in children, we evaluated children infected with SARS-CoV-2 and treated at the Wuhan Children’s Hospital, the only center assigned by the central government for treating infected children under 16 years of age in Wuhan. Both symptomatic and asymptomatic children with known contact with persons having confirmed or suspected SARS-CoV-2 infection were evaluated. Nasopharyngeal or throat swabs were obtained for detection of SARS-CoV-2 RNA by established methods.4 The clinical outcomes were monitored up to March 8, 2020.
Of the 1391 children assessed and tested from January 28 through February 26, 2020, a total of 171 (12.3%) were confirmed to have SARS-CoV-2 infection. Demographic data and clinical features are summarized in Table 1. (Details of the laboratory and radiologic findings are provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org.) The median age of the infected children was 6.7 years. Fever was present in 41.5% of the children at any time during the illness. Other common signs and symptoms included cough and pharyngeal erythema. A total of 27 patients (15.8%) did not have any symptoms of infection or radiologic features of pneumonia. A total of 12 patients had radiologic features of pneumonia but did not have any symptoms of infection. During the course of hospitalization, 3 patients required intensive care support and invasive mechanical ventilation; all had coexisting conditions (hydronephrosis, leukemia [for which the patient was receiving maintenance chemotherapy], and intussusception). Lymphopenia (lymphocyte count, <1.2×109 per liter) was present in 6 patients (3.5%). The most common radiologic finding was bilateral ground-glass opacity (32.7%). As of March 8, 2020, there was one death. A 10-month-old child with intussusception had multiorgan failure and died 4 weeks after admission. A total of 21 patients were in stable condition in the general wards, and 149 have been discharged from the hospital.
Table 1
Characteristic Value
Age  
Median (range) 6.7 yr (1 day–15 yr)
Distribution — no. (%)  
<1 yr 31 (18.1)
1–5 yr 40 (23.4)
6–10 yr 58 (33.9)
11–15 yr 42 (24.6)
Sex — no. (%)  
Male 104 (60.8)
Female 67 (39.2)
Diagnosis — no. (%)  
Asymptomatic infection 27 (15.8)
Upper respiratory tract infection 33 (19.3)
Pneumonia 111 (64.9)
Exposure or contact information — no. (%)  
Family cluster 154 (90.1)
Confirmed family members 131 (76.6)
Suspected family members 23 (13.5)
Unidentified source of infection 15 (8.8)
Contact with other suspected case 2 (1.2)
Signs and symptoms  
Cough — no. (%) 83 (48.5)
Pharyngeal erythema — no. (%) 79 (46.2)
Fever — no. (%) 71 (41.5)
Median duration of fever (range) — days 3 (1–16)
Highest temperature during hospitalization — no. (%)  
<37.5°C 100 (58.5)
37.5–38.0°C 16 (9.4)
38.1–39.0°C 39 (22.8)
>39.0°C 16 (9.4)
Diarrhea — no. (%) 15 (8.8)
Fatigue — no. (%) 13 (7.6)
Rhinorrhea — no. (%) 13 (7.6)
Vomiting — no. (%) 11 (6.4)
Nasal congestion — no. (%) 9 (5.3)
Tachypnea on admission — no. (%) 49 (28.7)
Tachycardia on admission — no. (%) 72 (42.1)
Oxygen saturation <92% during period of hospitalization — no. (%) 4 (2.3)
Abnormalities on computed tomography of the chest — no. (%)  
Ground-glass opacity 56 (32.7)
Local patchy shadowing 32 (18.7)
Bilateral patchy shadowing 21 (12.3)
Interstitial abnormalities 2 (1.2)
Epidemiologic Characteristics, Clinical Features, and Radiologic Findings of 171 Children with SARS-CoV-2 Infection.*
*
Percentages may not total 100 because of rounding.
The normal ranges of respiratory rate (in breaths per minute) were as follows: 40 to 60 for newborns, 30 to 40 for children younger than 1 year of age, 25 to 30 for those 1 to 3 years of age, 20 to 25 for those 4 to 7 years of age, 18 to 20 for those 8 to 14 years of age, and 12 to 20 for those older than 14 years of age. Tachypnea refers to a respiratory rate higher than the upper limit of the normal range according to age.
The normal ranges of pulse rate (in beats per minute) were as follows: 120 to 140 for newborns, 110 to 130 for children younger than 1 year of age, 100 to 120 for those 1 to 3 years of age, 80 to 100 for those 4 to 7 years of age, 70 to 90 for those 8 to 14 years of age, and 60 to 70 for those older than 14 years of age. Tachycardia refers to a pulse rate higher than the upper limit of the normal range according to age.
This report describes a spectrum of illness from SARS-CoV-2 infection in children. In contrast with infected adults, most infected children appear to have a milder clinical course. Asymptomatic infections were not uncommon.2 Determination of the transmission potential of these asymptomatic patients is important for guiding the development of measures to control the ongoing pandemic.
Xiaoxia Lu, M.D.
Liqiong Zhang, M.D.
Hui Du, M.D.
Wuhan Children’s Hospital, Wuhan, China
Jingjing Zhang, Ph.D.
Yuan Y. Li, Ph.D.
Jingyu Qu, Ph.D.
Wenxin Zhang, Ph.D.
Youjie Wang, Ph.D.
Shuangshuang Bao, Ph.D.
Ying Li, Ph.D.
Chuansha Wu, Ph.D.
Hongxiu Liu, Ph.D.
Huazhong University of Science and Technology, Wuhan, China
Wuhan Institute of Virology, Wuhan, China
Jianbo Shao, M.D.
Xuehua Peng, M.D.
Huazhong University of Science and Technology, Wuhan, China
Beijing Children’s Hospital, Beijing, China
Zhisheng Liu, M.D.
Yun Xiang, M.D.
Furong Zhang, M.D.
Wuhan Children’s Hospital, Wuhan, China
Rona M. Silva, Ph.D.
Kent E. Pinkerton, Ph.D.
University of California, Davis, Davis, CA
Kunling Shen, M.D.
Chinese National Clinical Research Center for Respiratory Diseases, Beijing, China
Han Xiao, Ph.D.
Institute of Maternal and Child Health, Wuhan, China
Shunqing Xu, M.D., Ph.D.
Wuhan Children’s Hospital, Wuhan, China [email protected]
Gary W.K. Wong, M.D.
Chinese University of Hong Kong, Shatin, China [email protected]
for the Chinese Pediatric Novel Coronavirus Study Team

Notes

This letter was published on March 18, 2020, at NEJM.org.
Drs. Lu, J. Zhang, Y.Y. Li, and D. Liu and Drs. Shen, Xu, and Wong contributed equally to this letter.
Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

Supplementary Material

Supplementary Appendix (nejmc2005073_appendix.pdf)
Disclosure Forms (nejmc2005073_disclosures.pdf)

References

1.
World Health Organization. Coronavirus disease 2019 (COVID-19): situation report — 50 (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200310-sitrep-50-covid-19.pdf?sfvrsn=55e904fb_2).
2.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 February 24 (Epub ahead of print).
3.
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med.
4.
World Health Organization. Country & technical guidance — coronavirus disease (COVID-19) (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance).

Information & Authors

Information

Published In

New England Journal of Medicine
Pages: 1663-1665

History

Published online: March 18, 2020
Published in issue: April 23, 2020

Topics

Authors

Authors

Xiaoxia Lu, M.D.1, Liqiong Zhang, M.D.1, Hui Du, M.D.1, Jingjing Zhang, Ph.D.2, Yuan Y. Li, Ph.D.2, Jingyu Qu, Ph.D.2, Wenxin Zhang, Ph.D.2, Youjie Wang, Ph.D.2, Shuangshuang Bao, Ph.D.2, Ying Li, Ph.D.2, Chuansha Wu, Ph.D.2, Hongxiu Liu, Ph.D.2, Di Liu, Ph.D.3 https://orcid.org/0000-0003-3693-2726, Jianbo Shao, M.D.4, Xuehua Peng, M.D.4, Yonghong Yang, M.D.5 https://orcid.org/0000-0002-8423-1652, Zhisheng Liu, M.D.6, Yun Xiang, M.D.6, Furong Zhang, M.D.6, Rona M. Silva, Ph.D.7, Kent E. Pinkerton, Ph.D.7, Kunling Shen, M.D.8, Han Xiao, Ph.D.9, Shunqing Xu, M.D., Ph.D.10, and Gary W.K. Wong, M.D.11, for the Chinese Pediatric Novel Coronavirus Study Team

Affiliations

1Wuhan Children’s Hospital, Wuhan, China
2Huazhong University of Science and Technology, Wuhan, China
3Wuhan Institute of Virology, Wuhan, China
4Huazhong University of Science and Technology, Wuhan, China
5Beijing Children’s Hospital, Beijing, China
6Wuhan Children’s Hospital, Wuhan, China
7University of California, Davis, Davis, CA
8Chinese National Clinical Research Center for Respiratory Diseases, Beijing, China
9Institute of Maternal and Child Health, Wuhan, China
10Wuhan Children’s Hospital, Wuhan, China
[email protected]
11Chinese University of Hong Kong, Shatin, China
[email protected]

Metrics & Citations

Metrics

Altmetrics

Citations

Export citation

Select the format you want to export the citation of this publication.

Cited by

  1. Clinical Epidemiological Characteristics and Risk Factors for Severity of SARS-CoV-2 Pneumonia in Pediatric Patients: A Hospital-Based Study in Vietnam, Cureus, (2024).https://doi.org/10.7759/cureus.58371
    Crossref
  2. Epidemiology and clinical features of SARS-CoV-2 infection in children and adolescents in the pre-Omicron era: A global systematic review and meta-analysis, Journal of Global Health, 14, (2024).https://doi.org/10.7189/jogh.14.05003
    Crossref
  3. Comprehensive analysis of the potential pathogenesis of COVID-19 infection and liver cancer, World Journal of Gastrointestinal Oncology, 16, 2, (436-457), (2024).https://doi.org/10.4251/wjgo.v16.i2.436
    Crossref
  4. Stratifying Disease Severity in Pediatric COVID-19: A Correlative Study of Serum Biomarkers and Lung Ultrasound—A Retrospective Observational Dual-Center Study, Diagnostics, 14, 4, (440), (2024).https://doi.org/10.3390/diagnostics14040440
    Crossref
  5. SARS-CoV-2 Seroprevalence in a Berlin Kindergarten Environment: A Cross-Sectional Study, September 2021, Children, 11, 4, (405), (2024).https://doi.org/10.3390/children11040405
    Crossref
  6. Hematological profile, inflammatory markers and serum liver enzymes in COVID 19 positive children vs. COVID 19 negative ones—a comparative study, Frontiers in Pediatrics, 12, (2024).https://doi.org/10.3389/fped.2024.1334591
    Crossref
  7. COVID-19 in children with bronchial asthma: aspects of comorbidity, CHILDREN INFECTIONS, 23, 1, (5-11), (2024).https://doi.org/10.22627/2072-8107-2024-23-1-5-11
    Crossref
  8. Kidney damage in children with COVID-19 (clinical observation), Journal Infectology, 15, 4, (148-151), (2024).https://doi.org/10.22625/2072-6732-2023-15-4-148-151
    Crossref
  9. Impact of “Long Covid” on Children: Global and Hong Kong Perspectives, Current Pediatric Reviews, 20, 1, (59-65), (2024).https://doi.org/10.2174/1573396319666221021154949
    Crossref
  10. Features of severe forms of new coronavirus infection (COVID-19) in children, Pediatrician (St. Petersburg), 14, 5, (5-13), (2024).https://doi.org/10.17816/PED625937
    Crossref
  11. See more
Loading...

View Options

View options

PDF

View PDF

Media

Figures

Other

Tables

Share

Share

CONTENT LINK

Share